Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2026-09-04 17:02:24 ET · period of report 2026-09-02 · accession 0001797826-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-04 17:02 | 2026-09-02 | DNLI | Thornberry Nancy | Dir | S - Sale | $22.90 | -11.4K | 19.7K | -37% | -$261.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-02 | S | D | 10,824 | $22.85 | 20,301 | D | — | — | (F1) The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026. (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.54 to $23.52 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 6,408 Unvested RSUs. |
| 2 | Common | Common Stock | 2026-09-02 | S | D | 615 | $23.74 | 19,686 | D | — | — | (F1) The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026. (F4) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.59 to $23.85 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 6,408 Unvested RSUs. |